Published in Heart on March 29, 2005
Molecular and cellular aspects of calcific aortic valve disease. Circ Res (2013) 1.12
Insulin resistance and subclinical abnormalities of global and regional left ventricular function in patients with aortic valve sclerosis. Cardiovasc Diabetol (2014) 0.84
Acute myocardial infarction in patients with versus without aortic valve sclerosis and effect of statin therapy (from the Heart and Soul Study). Am J Cardiol (2007) 0.82
Pathophysiology of valvular heart disease. Exp Ther Med (2016) 0.78
The Preoperative Patient With a Systolic Murmur. Anesth Pain Med (2015) 0.77
Echocardiographic integrated backscatter for detecting progression and regression of aortic valve calcifications in rats. Cardiovasc Ultrasound (2013) 0.77
Study of Aortic Valve Sclerosis as A Marker of Atherosclerosis in Acute Coronary Syndromes. J Clin Diagn Res (2016) 0.75
Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. N Engl J Med (1999) 8.14
Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J Am Coll Cardiol (1997) 7.45
Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension (2001) 4.70
Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies. Circulation (1994) 4.32
Medial artery calcification. A neglected harbinger of cardiovascular complications in non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol (1996) 3.77
Prospective study of asymptomatic valvular aortic stenosis. Clinical, echocardiographic, and exercise predictors of outcome. Circulation (1997) 3.72
Calcification of the aortic arch: risk factors and association with coronary heart disease, stroke, and peripheral vascular disease. JAMA (2000) 3.36
Abdominal aortic calcific deposits are an important predictor of vascular morbidity and mortality. Circulation (2001) 3.18
HMG CoA reductase inhibitor (statin) and aortic valve calcium. Lancet (2002) 2.59
Progression of aortic valve calcification: association with coronary atherosclerosis and cardiovascular risk factors. Circulation (2001) 2.55
Mitral annular calcification predicts cardiovascular morbidity and mortality: the Framingham Heart Study. Circulation (2003) 2.39
Mild and moderate aortic stenosis. Natural history and risk stratification by echocardiography. Eur Heart J (2004) 2.11
Adverse outcome in aortic sclerosis is associated with coronary artery disease and inflammation. J Am Coll Cardiol (2004) 1.91
Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis in older persons. Am J Cardiol (2001) 1.72
The risk of the development of aortic stenosis in patients with "benign" aortic valve thickening. Arch Intern Med (2002) 1.48
Abdominal aortic calcific deposits are associated with increased risk for congestive heart failure: the Framingham Heart Study. Am Heart J (2002) 1.32
Aortic valve sclerosis is associated with systemic endothelial dysfunction. J Am Coll Cardiol (2003) 1.18
Comparison of frequency of new coronary events in older subjects with and without valvular aortic sclerosis. Am J Cardiol (1999) 1.01
Progression of aortic valve sclerosis to aortic stenosis. Am J Cardiol (2003) 1.00
Inflammation, infection, and aortic valve sclerosis; Insights from the Olmsted County (Minnesota) population. Atherosclerosis (2004) 1.00
Epidemiology of mitral annular calcification and its predictive value for coronary events in African Americans: the Jackson Cohort of the Atherosclerotic Risk in Communities Study. Am Heart J (2004) 0.99
Aortic valve sclerosis relates to cardiovascular events in patients with hypertension (a LIFE substudy). Am J Cardiol (2005) 0.97
Relation of aortic valve sclerosis to risk of coronary heart disease in African-Americans. Am J Cardiol (2005) 0.96
Quantitative assessment of aortic sclerosis using ultrasonic backscatter. J Am Soc Echocardiogr (2004) 0.89
Association of aortic stenosis with platelet hyperaggregability and impaired responsiveness to nitric oxide. Am J Cardiol (2002) 0.87
Aortic sclerosis--a window to the coronary arteries? N Engl J Med (1999) 0.86
Effect of losartan versus atenolol on aortic valve sclerosis (a LIFE substudy). Am J Cardiol (2004) 0.86
Relation of aortic valve sclerosis to carotid artery intima-media thickening in healthy subjects. Am J Cardiol (2004) 0.83
Association of aortic valve calcium detected by electron beam computed tomography with echocardiographic aortic valve disease and with calcium deposits in the coronary arteries and thoracic aorta. Am J Cardiol (2004) 0.79
Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation (1999) 3.06
Effects of a home-based intervention among patients with congestive heart failure discharged from acute hospital care. Arch Intern Med (1998) 2.65
Effects of home-based intervention on unplanned readmissions and out-of-hospital deaths. J Am Geriatr Soc (1998) 2.49
Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial. Circulation (2000) 2.49
Heart failure in older people: the epidemic we had to have. Med J Aust (2001) 2.03
Is informed consent to clinical trials an "upside selective" process in acute coronary syndromes? Am Heart J (2000) 1.74
N-acetylcysteine in combination with nitroglycerin and streptokinase for the treatment of evolving acute myocardial infarction. Safety and biochemical effects. Circulation (1995) 1.58
Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial. Eur Heart J (2000) 1.55
Nitroglycerin tolerance in human vessels: evidence for impaired nitroglycerin bioconversion. Circulation (2000) 1.53
Nitrate resistance in platelets from patients with stable angina pectoris. Circulation (1999) 1.49
Utility of a weight-based heparin nomogram for patients with acute coronary syndromes. Intern Med J (2003) 1.46
Cardiovascular critical event pathways for the progression of heart failure; a report from the ATLAS study. Eur Heart J (2001) 1.46
Beneficial clinical effects of perhexiline in patients with stable angina pectoris and acute coronary syndromes are associated with potentiation of platelet responsiveness to nitric oxide. Eur Heart J (2002) 1.44
Acute myocardial uptake of digoxin in humans: correlation with hemodynamic and electrocardiographic effects. J Am Coll Cardiol (1990) 1.41
Prolonged beneficial effects of a home-based intervention on unplanned readmissions and mortality among patients with congestive heart failure. Arch Intern Med (1999) 1.33
Calcium antagonists: a new class of drugs. Pharmacol Ther (1983) 1.28
Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data. J Thromb Haemost (2010) 1.25
Hypertensive responses induced by phenylpropanolamine in anorectic and decongestant preparations. Lancet (1980) 1.24
Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone. Biochem Pharmacol (1996) 1.22
Perhexiline maleate treatment for severe angina pectoris--correlations with pharmacokinetics. Int J Cardiol (1986) 1.10
Potentiation of the cardiovascular effects of nitroglycerin by N-acetylcysteine. Circulation (1983) 1.07
Peripherally inserted central catheters revisited. Am J Surg (1998) 1.01
Potentiation of coronary vasoconstriction by beta-adrenergic blockade in patients with coronary artery disease. Circulation (1983) 1.01
Nitroglycerin-induced tolerance affects multiple sites in the organic nitrate bioconversion cascade. J Pharmacol Exp Ther (1989) 0.99
S-nitrosothiols as vasodilators: implications regarding tolerance to nitric oxide-containing vasodilators. Br J Pharmacol (1989) 0.98
Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial. The Assessment of Treatment with Lisinopril and Survival. Arch Intern Med (2001) 0.94
Relationship between plasma perhexiline concentration and symptomatic status during short-term perhexiline therapy. Ther Drug Monit (1996) 0.92
Amelioration of renal ischaemia-reperfusion injury by liposomal delivery of curcumin to renal tubular epithelial and antigen-presenting cells. Br J Pharmacol (2012) 0.91
Prevention and reversal of tolerance to nitroglycerine with N-acetylcysteine. J Cardiovasc Pharmacol (1985) 0.90
Drugs and impaired male sexual function. Drugs (1979) 0.90
Neovascular complications associated with rubeosis iridis and peripheral retinal detachment after retinal detachment surgery. Am J Ophthalmol (1998) 0.89
High-performance liquid chromatographic assay of perhexiline maleate in plasma. J Pharm Sci (1981) 0.89
Effect of perhexiline and oxfenicine on myocardial function and metabolism during low-flow ischemia/reperfusion in the isolated rat heart. J Cardiovasc Pharmacol (2000) 0.88
Verapamil hepatotoxicity: a hypersensitivity reaction. Am Heart J (1986) 0.87
Effects of captopril (SQ 14,225) in a patient with primary pulmonary hypertension. Postgrad Med J (1981) 0.87
Determinants of in vitro nitroglycerin tolerance induction and reversal: influence of dose regimen, nitrate-free period, and sulfhydryl supplementation. J Cardiovasc Pharmacol (1989) 0.86
Cardiovascular responses to partial and total immersion in man. J Physiol (1969) 0.86
Home-based intervention: the next step in treatment of chronic heart failure? Eur Heart J (2000) 0.86
Recent developments in nitrate therapy of ischaemic heart disease. Med J Aust (1987) 0.84
Short-term myocardial uptake of lidocaine and mexiletine in patients with ischemic heart disease. Circulation (1986) 0.83
Nitroglycerin tolerance at the platelet level in patients with angina pectoris. Am J Cardiol (1997) 0.83
Prevention of aortic valve stenosis: a realistic therapeutic target? Pharmacol Ther (2012) 0.83
Determinants of insulin responsiveness in young women: Impact of polycystic ovarian syndrome, nitric oxide, and vitamin D. Nitric Oxide (2011) 0.82
Acute effects of vitamin C on platelet responsiveness to nitric oxide donors and endothelial function in patients with chronic heart failure. J Cardiovasc Pharmacol (2001) 0.82
Regional differences in the characteristics and treatment of patients participating in an international heart failure trial. The Assessment of Treatment with Lisinopril and Survival (ATLAS) Trial Investigators. J Card Fail (1998) 0.82
Reversal of human platelet aggregation by low concentrations of nitroglycerin in vitro in normal subjects. Am J Cardiol (1992) 0.82
D-dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation--observations from the ARISTOTLE trial. J Thromb Haemost (2014) 0.82
Surgery for carotid artery stenosis following neck irradiation. Ann Vasc Surg (2001) 0.81
Comparison of negative inotropic potency, reversibility, and effects on calcium influx of six calcium channel antagonists in cultured myocardial cells. Br J Pharmacol (1985) 0.81
Baseline clinical characteristics of patients recruited into the assessment of treatment with lisinopril and survival study. Eur J Heart Fail (1999) 0.81
Indinavir nephropathy. N Engl J Med (1997) 0.81
Perhexiline improves symptomatic status in elderly patients with severe aortic stenosis. Aust N Z J Med (1997) 0.81
Is perhexiline essential for the optimal management of angina pectoris? Aust N Z J Med (1995) 0.81
Low doses vs. high doses of the angiotensin converting-enzyme inhibitor lisinopril in chronic heart failure: a cost-effectiveness analysis based on the Assessment of Treatment with Lisinopril and Survival (ATLAS) study. The ATLAS Study Group. Eur J Heart Fail (2000) 0.80
Usefulness of early exercise testing after non-Q-wave myocardial infarction in predicting prognosis. Am J Cardiol (1986) 0.80
The effects of perhexiline on the rat coronary vasculature. Eur J Pharmacol (1999) 0.80
Attenuation of coronary vascular resistance by selective alpha 1-adrenergic blockade in patients with coronary artery disease. J Am Coll Cardiol (1985) 0.80
Myocardial uptake of drugs and clinical effects. Clin Pharmacokinet (1987) 0.80
Tolerance induction by transdermal glyceryl trinitrate in rats. Eur J Pharmacol (1999) 0.80
High-performance liquid chromatographic determination of sotalol in plasma. I. Application to the disposition of sotalol enantiomers in humans. J Chromatogr (1992) 0.80
Use of dopamine and prazosin combined in the treatment of cardiogenic shock. Med J Aust (1980) 0.79
Nitrate therapy is an alternative to furosemide/morphine therapy in the management of acute cardiogenic pulmonary edema. J Card Fail (1998) 0.79
Suppressed anti-aggregating and cGMP-elevating effects of sodium nitroprusside in platelets from patients with stable angina pectoris. Naunyn Schmiedebergs Arch Pharmacol (1996) 0.79
The endogenous NOS inhibitor asymmetric dimethylarginine (ADMA) predicts LV mass independent of afterload. Nitric Oxide (2011) 0.79
Multiple agonist induction of aggregation: an approach to examine anti-aggregating effects in vitro. Platelets (1996) 0.79
Determinants of platelet responsiveness to nitric oxide in patients with chronic heart failure. Eur J Heart Fail (2004) 0.79
Antiplatelet effects of nitroglycerin in healthy subjects and in patients with stable angina pectoris. J Cardiovasc Pharmacol (1993) 0.79
Prediction of outcome after revascularization in patients with poor left ventricular function. Ann Thorac Surg (1996) 0.79
Poles apart, but are they the same? A comparative study of Australian and Scottish patients with chronic heart failure. Eur J Heart Fail (2001) 0.79
Lack of interaction between digoxin and quinidine in cultured heart cells. J Pharmacol Exp Ther (1982) 0.78
Nitrate tolerance induced by nicorandil or nitroglycerin is associated with minimal loss of nicorandil vasodilator activity. J Cardiovasc Pharmacol (1990) 0.78
Hypertension and postural hypotension induced by phenylpropanolamine (Trimolets). Med J Aust (1979) 0.78
Can a nurse trained in coronary care expedite emergency department management of patients with acute coronary syndromes? Heart Lung (2001) 0.78
Stable angina and acute coronary syndromes are associated with nitric oxide resistance in platelets. J Am Coll Cardiol (2001) 0.78
Extraction of plasma prorenin by human heart. Lancet (1986) 0.78
Measurement of penicillamine and N-acetylcysteine in human blood by high-performance liquid chromatography and electrochemical detection. J Chromatogr (1986) 0.78
Development of a regimen for rapid initiation of perhexiline therapy in acute coronary syndromes. Intern Med J (2004) 0.78
Myocardial effect compartment modeling of metoprolol and sotalol: importance of myocardial subsite drug concentration. J Pharm Sci (1998) 0.77
Perhexiline maleate in the treatment of severe angina pectoris. Med J Aust (1979) 0.77
Effects of glyceryl trinitrate tolerance on vascular responsiveness to constrictor agents in bovine isolated coronary artery. Clin Exp Pharmacol Physiol (1995) 0.77
N-Acetylcysteine potentiates nitroglycerin-induced reversal of platelet aggregation. J Cardiovasc Pharmacol (1996) 0.77
The nitric oxide redox sibling nitroxyl partially circumvents impairment of platelet nitric oxide responsiveness. Nitric Oxide (2013) 0.77
Comparative trial of mexiletine and lignocaine in the treatment of early ventricular tachyarrhythmias after acute myocardial infarction. J Cardiovasc Pharmacol (1981) 0.77
S-nitrosothiol modulation of tolerance to glyceryl trinitrate in bovine isolated coronary artery. Eur J Pharmacol (1994) 0.77
Endothelin B receptor-mediated vasoconstriction induced by endothelin A receptor antagonist. Cardiovasc Res (1998) 0.77
Sotalol-induced torsade de pointes: management with magnesium infusion. Postgrad Med J (1992) 0.76
Magnetic resonance angiography in the preoperative evaluation of abdominal aortic aneurysms. Am J Surg (1993) 0.76
Inhibition of long-chain fatty acid metabolism does not affect platelet aggregation responses. Eur J Pharmacol (1998) 0.76
Lack of inhibition of glyceryl trinitrate by diphenyleneiodonium in bovine coronary artery. Eur J Pharmacol (1996) 0.76
Effects of guanylyl cyclase and protein kinase G inhibitors on vasodilatation in non-tolerant and tolerant bovine coronary arteries. Eur J Pharmacol (1999) 0.76
Persistence of the coronary slow flow phenomenon. Am J Cardiol (2001) 0.75
Effect of trimetazidine on carnitine palmitoyltransferase-1 in the rat heart. Cardiovasc Drugs Ther (1998) 0.75
Postextrasystolic potentiation in patients with ischaemic heart disease: influence of inotropic agents. Br J Clin Pharmacol (1995) 0.75
ST elevation secondary to microvascular dysfunction. J Am Coll Cardiol (1999) 0.75
Nitrates for myocardial infarction. Lancet (1998) 0.75
Impaired responsiveness of platelets from patients with stable angina pectoris to antiaggregating and cyclicAMP-elevating effects of prostaglandin E1. J Cardiovasc Pharmacol (1995) 0.75
Redefining the natural history of calcific aortic stenosis: lessons from Laennec. J Intern Med (2012) 0.75
Haemodynamic effects of a single low dose of prazosin in patients with chronic congestive cardiac failure correlations with pharmacokinetics. Clin Exp Pharmacol Physiol (1984) 0.75
The prevalence of ST-segment depression on ambulatory electrocardiographic monitoring during daily life in high-risk asymptomatic police officers. J Cardiovasc Risk (1994) 0.75